Novo's stock continued to climb after the holiday weekend, reaching a new market cap of $429 billion Tuesday, as LVMH's stock declined. The company's rise also makes Novo more valuable than the GDP of its home country, Denmark .
The injectables are part of a growing market for GLP-1s, drugs that mimic a hormone in the body to slow digestion, which have been around for some time. But stronger weight loss results compared to previous drugs in the category catapulted Ozempic and Wegovy into the mainstream.of some doses — a problem that Novo Nordisk is actively trying to solve with its contract manufacturers. But even so, the drugmaker has said it is unlikely to meet the skyrocketing demand in the near future.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
स्रोत: YahooFinanceCA - 🏆 47. / 63 और पढो »